Literature DB >> 31898194

Severe obstructive sleep apnea is associated with circulating microRNAs related to heart failure, myocardial ischemia, and cancer proliferation.

Lunara S Freitas1,2, André C Silveira3, Franco C Martins4, Valéria Costa-Hong2, Adriana Lebkuchen5, Karina H M Cardozo5, Fernanda M Bernardes2, Luiz A Bortolotto2, Geraldo Lorenzi-Filho4, Edilamar M Oliveira3, Luciano F Drager6,7.   

Abstract

PURPOSE: Obstructive sleep apnea (OSA) is associated with multiple comorbid conditions including cardiovascular diseases and cancer. There is a growing interest in exploring biomarkers to understand the related mechanisms and improve the risk stratification of OSA. Circulating microRNAs (miRNAs) are single noncoding strands of nearly 22 nucleotides that posttranscriptionally regulate target gene expression. Our aim was to identify miRNA profiles associated with OSA.
METHODS: We studied 48 male subjects, mostly Caucasian (63%) and overweight, divided by polysomnography into the no OSA control group (n = 6), mild OSA group (n = 12), moderate OSA group (n = 15), and severe OSA group (n = 15). The study groups were matched for age, body mass index (BMI), and body fat composition. miRNA profiles were measured from peripheral whole blood using two steps: (1) microarray analysis comprising more than 2500 miRNAs in a subsample of 12 subjects (three from each group); and (2) validation phase using real-time quantitative polymerase chain reaction (RTqPCR).
RESULTS: The microarray assessment identified 21 differentially expressed miRNAs among the groups. The RT-qPCR assessment showed that miR-1254 and miR-320e presented a gradual increase in expression parallel to OSA severity. Linear regression analysis showed that severe OSA was independently associated with miR-1254 (ß = 68.4; EP = 29.8; p = 0.02) and miR-320e (ß = 76.1; EP = 31.3; p = 0.02).
CONCLUSION: Severe OSA is independently associated with miRNAs that are involved in heart failure (miR-1254), myocardial ischemia/reperfusion (miR-320e), and cell proliferation in some cancer types (miR-1254 and miR-320e). Future investigations addressing whether these miRs may provide prognostic information in OSA are needed.

Entities:  

Keywords:  Biomarkers; Cancer; Cardiovascular disease; MicroRNAs; Sleep apnea

Year:  2020        PMID: 31898194     DOI: 10.1007/s11325-019-02003-1

Source DB:  PubMed          Journal:  Sleep Breath        ISSN: 1520-9512            Impact factor:   2.816


  5 in total

1.  Proteomic biomarkers of sleep apnea.

Authors:  Aditya Ambati; Yo-El Ju; Ling Lin; Alexander N Olesen; Henriette Koch; Julien Jacques Hedou; Eileen B Leary; Vicente Peris Sempere; Emmanuel Mignot; Shahrad Taheri
Journal:  Sleep       Date:  2020-11-12       Impact factor: 5.849

2.  Fragmentation of Rest/Activity Patterns in Community-Based Elderly Individuals Predicts Incident Heart Failure.

Authors:  Lei Gao; Andrew S P Lim; Patricia M Wong; Arlen Gaba; Longchang Cui; Lei Yu; Aron S Buchman; David A Bennett; Kun Hu; Peng Li
Journal:  Nat Sci Sleep       Date:  2020-05-27

3.  Analysis of nocturnal, hypoxia-induced miRNAs in sleep apnea patients.

Authors:  Philip Roger Goody; Lisa Nachtsheim; Mohammed Rabiul Hosen; Miriam von Krosigk; Dominik Christmann; Jens Peter Klussmann; Andreas Zietzer; Nils Breitrück; Felix Jansen; Stefanie Jansen
Journal:  PLoS One       Date:  2022-03-04       Impact factor: 3.240

Review 4.  Emerging Challenges of Radiation-Associated Cardiovascular Dysfunction (RACVD) in Modern Radiation Oncology: Clinical Practice, Bench Investigation, and Multidisciplinary Care.

Authors:  Moon-Sing Lee; Dai-Wei Liu; Shih-Kai Hung; Chih-Chia Yu; Chen-Lin Chi; Wen-Yen Chiou; Liang-Cheng Chen; Ru-Inn Lin; Li-Wen Huang; Chia-Hui Chew; Feng-Chun Hsu; Michael W Y Chan; Hon-Yi Lin
Journal:  Front Cardiovasc Med       Date:  2020-02-21

5.  Differential expression of microRNAs in xenografted Lewis lung carcinomas subjected to intermittent hypoxia: a next-generation sequence analysis.

Authors:  Xiao-Bin Zhang; Xiu-Li Lin; Xin-Yu Wu; Yi-Ming Zeng; Xiao-Yang Chen; Xiongbiao Luo; Hui-Qing Zeng
Journal:  Transl Cancer Res       Date:  2020-07       Impact factor: 1.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.